Alvimedica
FOR IMMEDIATE RELEASE
Scientific sessions endorsed by Alvimedica Medical Technologies during EuroPCR 2014 in Paris
May 16th, 2014 - Alvimedica Medical Technologies, a leading European company in interventional cardiology, will endorse 3 relevant scientific sessions during the EuroPCR2014 congress in Paris. Alvimedica is willing to collaborate with worldwide physicians to intimately understand their daily challenges and needs in order to contribute to improve patients’ clinical outcome. The sessions’ specific program and content has been developed in order to provide attendees an update on the latest advancements in device technologies and procedural techniques.
Tuesday 20th of May from 17.00 to 18.30 – Room 351 - “How should I treat?” session titled “Cre8™: unique technology in challenging daily practice”.
Challenging cases on patients with dual antiplatelet therapy constraints and high-risk of restenosis will trigger an in-depth discussion on the issues an intervetional cardiologist faces everyday and the most correct approaches to solve them.
Wednesday 21st of May from 16:50 to 18:20 – Room 241 - Symposium entitled “Meeting the unmet: the Cre8 polymer-free DES”.
International KOLs will update the audience on unique Cre8™ Drug Eluting Stent (DES), its latest clinical results and the foreseen clinical benefits the polymer-free technology may provide to advance today’s DES efficacy and safety.
Thursday 22st of May from 12.30 to 14.30 – Room Theater Bleu - Tool & Techniques session titled “Contemporary techniques for coronary CTO revascularization: sharing experience in a global world”.
Two live cases will allow attendees to learn how to improve PCI success in coronary CTO by matching techniques to anatomical & clinical characteristics as well as understanding how to optimize patients long-term outcomes interacting with experienced operators and recognized KOLs.
About Alvimedica
Alvimedica is a young, agile company devoted to developing minimally-invasive medical technologies for medical professionals looking for the next level of innovation in the operating room. We firmly believe that working closely with physicians is the best way to improve our product solutions and services; ‘co-creation’ in the interest of patients around the globe – that’s what shapes us as a company. We invite medical professionals to visit our Centers of Excellence in R&D in Turkey, Italy and the Netherlands, to present and discuss new treatment options. Our ‘co-creation approach’ results in a growing and innovative product portfolio for both endovascular and interventional cardiology.
For more information on Alvimedica Medical Technologies: www.alvimedica.com